The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma
Jin-Liang Zhu
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Jin-Liang Zhu and Yong-Xi song contributed equally to this work.Search for more papers by this authorYong-Xi Song
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Jin-Liang Zhu and Yong-Xi song contributed equally to this work.Search for more papers by this authorCorresponding Author
Zhen-Ning Wang
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Address for correspondence: Z-N Wang, Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City 110001, China. e-mail: [email protected]Search for more papers by this authorPeng Gao
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorMei-Xian Wang
Department of Tumor Pathology and Surgical Oncology, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorYu-Lan Dong
Department of Tumor Pathology and Surgical Oncology, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorCheng-Zhong Xing
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorHui-Mian Xu
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorJin-Liang Zhu
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Jin-Liang Zhu and Yong-Xi song contributed equally to this work.Search for more papers by this authorYong-Xi Song
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Jin-Liang Zhu and Yong-Xi song contributed equally to this work.Search for more papers by this authorCorresponding Author
Zhen-Ning Wang
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Address for correspondence: Z-N Wang, Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City 110001, China. e-mail: [email protected]Search for more papers by this authorPeng Gao
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorMei-Xian Wang
Department of Tumor Pathology and Surgical Oncology, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorYu-Lan Dong
Department of Tumor Pathology and Surgical Oncology, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorCheng-Zhong Xing
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorHui-Mian Xu
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China
Search for more papers by this authorAbstract
Aims
Mesenchyme forkhead 1 (FoxC2) is an epithelial–mesenchymal transition (EMT)-inducing factor. Previous studies have demonstrated that FoxC2 binds directly to the promoter region of p120-catenin (p120ctn). The aim of this study was to investigate the clinical significance of FoxC2 expression and the inter-relationship between FoxC2 and p120ctn, in gastric cancer.
Methods and results
Immunohistochemistry was used to examine the expression of FoxC2 and p120ctn proteins in 325 gastric cancer samples. Staining for FoxC2 in cancer tissues was markedly stronger than in normal tissues. High FoxC2 expression was associated significantly with differentiation, invasion depth, lymph node metastasis and tumour stage. Patients with high FoxC2 expression or low p120ctn expression had a poor prognosis. In the high p120ctn expression group, the prognosis for patients with low FoxC2 expression was better than for the high FoxC2 group. Moreover, stepwise Cox regression showed that p120ctn was an independent prognostic factor, but FoxC2 in combination with p120ctn was not correlated significantly with survival.
Conclusions
We found that FoxC2 and p120ctn play important roles in the progression and prognosis of gastric cancer. Moreover, FoxC2 and p120ctn should be evaluated further as novel biomarkers and therapeutic targets for gastric cancer treatment.
References
- 1Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig. Dis. 2010; 28; 600–603.
- 2Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int. J. Cancer 2010; 127; 2893–2917.
- 3Murray G, Duncan M, Arbuckle E, Melvin W, Fothergill J. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998; 43; 791–797.
- 4Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2; 442–454.
- 5Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell 2009; 139; 871–890.
- 6Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial–mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 2009; 119; 1438–1449.
- 7Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from e-cadherin to n-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 2007; 13; 7003–7011.
- 8Iwatsuki M, Mimori K, Yokobori T et al. Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010; 101; 293–299.
- 9Mani SA, Yang J, Brooks M et al. Mesenchyme forkhead 1 (foxc2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl Acad. Sci. USA 2007; 104; 10069–10074.
- 10Yu YH, Chen HA, Chen PS et al. Mir-520h-mediated foxc2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 2013; 32; 431–443.
- 11Nishida N, Mimori K, Yokobori T et al. Foxc2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2011; 18; 535–542.
- 12Jiang W, Pang XG, Wang Q, Shen YX, Chen XK, Xi JJ. Prognostic role of twist, slug, and foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin. Lung Cancer 2012; 13; 280–287.
- 13Peinado H, Olmeda D, Cano A. Snail, zeb and bhlh factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 2007; 7; 415–428.
- 14Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008; 14; 818–829.
- 15Uchikado Y, Okumura H, Ishigami S et al. Increased slug and decreased e-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer 2011; 14; 41–49.
- 16Jouppila-Matto A, Narkio-Makela M, Soini Y et al. Twist and snail expression in pharyngeal squamous cell carcinoma stroma is related to cancer progression. BMC Cancer 2011; 11; 350.
- 17Kyo S, Sakaguchi J, Ohno S et al. High twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum. Pathol. 2006; 37; 431–438.
- 18Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J. Cell Biol. 2003; 163; 525–534.
- 19Reynolds AB, Carnahan RH. Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer. Semin. Cell Dev. Biol. 2004; 15; 657–663.
- 20Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res. 2005; 65; 10938–10945.
- 21Jawhari AU, Noda M, Pignatelli M, Farthing M. Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma. J. Pathol. 1999; 189; 180–185.
10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 22Liu Y, Li QC, Miao Y et al. Ablation of p120-catenin enhances invasion and metastasis of human lung cancer cells. Cancer Sci. 2009; 100; 441–448.
- 23Mortazavi F, An J, Dubinett S, Rettig M. P120-catenin is transcriptionally downregulated by foxc2 in non-small cell lung cancer cells. Mol. Cancer Res. 2010; 8; 762–774.
- 24 SR Hamilton, LA Aaltonen eds. Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours, vol. 2. Lyon, France: IARC Press, 2000.
- 25Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55; 237–241.
- 26Resnick MB, Gavilanez M, Newton E et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum. Pathol. 2005; 36; 886–892.
- 27Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52; 6735–6740.
- 28Natalwala A, Spychal R, Tselepis C. Epithelial–mesenchymal transition mediated tumourigenesis in the gastrointestinal tract. World J. Gastroenterol. 2008; 14; 3792–3797.
- 29Alves CC, Rosivatz E, Schott C et al. Slug is overexpressed in gastric carcinomas and may act synergistically with sip1 and snail in the down-regulation of e-cadherin. J. Pathol. 2007; 211; 507–515.
- 30Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, Kim WH. Prognostic importance of epithelial–mesenchymal transition-related protein expression in gastric carcinoma. Histopathology 2009; 54; 442–451.
- 31Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R. Differential expression of the epithelial–mesenchymal transition regulators snail, sip1, and twist in gastric cancer. Am. J. Pathol. 2002; 161; 1881–1891.
- 32Watanabe T, Kobunai T, Yamamoto Y et al. Gene expression of mesenchyme forkhead 1 (foxc2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int. Surg. 2011; 96; 207–216.
- 33Sano H, Leboeuf JP, Novitskiy SV et al. The foxc2 transcription factor regulates tumor angiogenesis. Biochem. Biophys. Res. Commun. 2010; 392; 201–206.
- 34Hayashi H, Kume T. Forkhead transcription factors regulate expression of the chemokine receptor cxcr4 in endothelial cells and cxcl12-induced cell migration. Biochem. Biophys. Res. Commun. 2008; 367; 584–589.
- 35Hayashi H, Sano H, Seo S, Kume T. The foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J. Biol. Chem. 2008; 283; 23791–23800.
- 36Hayashi H, Kume T. Foxc2 transcription factor as a regulator of angiogenesis via induction of integrin beta3 expression. Cell. Adh. Migr. 2009; 3; 24–26.
- 37Reynolds AB, Herbert L, Cleveland JL, Berg ST, Gaut JR. P120, a novel substrate of protein tyrosine kinase receptors and of p60v-src, is related to cadherin-binding factors beta-catenin, plakoglobin and armadillo. Oncogene 1992; 7; 2439–2445.
- 38Yanagisawa M, Anastasiadis PZ. P120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness. J. Cell Biol. 2006; 174; 1087–1096.
- 39Wijnhoven BP, Pignatelli M, Dinjens WN, Tilanus HW. Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J. Surg. Oncol. 2005; 92; 116–123.
- 40Chung Y, Lam AK, Luk JM et al. Altered e-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2007; 14; 3260–3267.
Citing Literature
